3 Skyrocketing MedTech Stocks That Might Lose Steam in 2026

MedTech is navigating a slower-growth, easing-inflation macro backdrop with selective hospital capital spending and supply-chain pressures, but remains relatively defensive due to persistent demand and innovation. Zacks highlights three names that outperformed over the past year—TransMedics (TMDX +101.4%), Hims & Hers (HIMS +32.6%) and Globus Medical (GMED +3.8%)—noting 2026 consensus EPS/revenue estimates: GMED EPS +3.9%/revs +7.9%, TMDX EPS +2.4%/revs +20.4%, HIMS EPS +22.3%/revs +17.6%. The piece cites structural upside from AI/automation (AI in healthcare estimated at $36.96B in 2025 to $613.81B by 2034, ~36.8% CAGR) while warning that macro normalization, selective hospital spending and competition could pressure richly valued names.

Analysis

Market structure: Winners will be MedTech companies tied to efficiency, outpatient migration and software/AI-enabled recurring revenue (subscription telehealth, diagnostics AI, automation kits); losers are capital-equipment vendors dependent on elective-procedure volume in cash-constrained hospitals. Pricing power will bifurcate — software/consumables with recurring margins can raise prices 3–5% annually while one-off capex faces 0–2% pricing pressure as procurement is selective. Supply-demand: near-term supply shocks (transportation, components) keep margins volatile ±200–400bp for exposed OEMs; demand shifts toward lower-capex outpatient solutions.

Risk assessment: Tail risks include reimbursement cuts (Medicare/insurer rate change ≥5% within 12–18 months), sudden supply-chain embargoes, or FDA/US competition probes that could erase 20–40% of equity value for exposed names. Immediate (days): earnings/guidance reactions; short-term (3–9 months): hospital capex cycles and CPI prints; long-term (2–5 years): structural AI adoption and demographic demand. Hidden dependencies include clinical staffing levels driving utilization and third-party logistics partnerships (e.g., Mercedes-Benz fleet) creating single-vendor operational risk. Key catalysts: US CPI <3% and Fed cuts expectations, hospital procurement budgets announced in Q1 2026, and major FDA clearances.

Trade implications: Direct: establish a 2–3% long position in HIMS (HIMS) with a 9–12 month horizon targeting +30–60% if subscriber ARPU growth >10% YoY; risk 20% stop. Short 2% position or buy a 3–6 month put spread on TransMedics (TMDX) to hedge momentum risk; target 15–25% downside on multiple compression. Pair trade: long GMED (1.5–2%) vs short TMDX (1.5–2%) to capture relative risk-off: GMED EPS growth ~+3.9% vs TMDX high expected revenue growth already priced. Use options: buy 9–12 month LEAP calls on HIMS and 3–6 month put spreads on TMDX to limit capital.

Contrarian angles: Consensus underrates the runway for AI-enabled services — companies that convert hardware sales into software subscriptions can re-rate 200–400bp higher in margins over 3 years; HIMS is underappreciated if M&A (Livewell) yields cross-sell lift >10% ARPU. Reaction may be overdone on TMDX’s short-term re-rating given the unique logistics moat; consider small, conditional add-on (additional 1–2% position) on a price pullback >15% or after demonstrable fleet utilization metrics. Historical parallel: 2013–2016 MedTech consolidation shows durable winners were recurring-revenue software/consumable hybrids, not pure-capex vendors.

Key Decisions for Investors

• Establish a 2–3% long position in Hims & Hers (HIMS) using either equity or a 9–12 month LEAP call (delta ~0.30) targeting +30–60% if subscriber ARPU growth >10% YoY; set a hard 20% stop-loss and reassess after Q1 2026 results.
• Open a 1.5–2% short or buy a 3–6 month put spread on TransMedics (TMDX) to hedge momentum risk; structure as 1×0.5 ratio (buy ATM put, sell further OTM put) targeting 15–25% downside if revenue multiple compresses or Q1 2026 guidance disappoints.
• Initiate a pair trade: long Globus Medical (GMED) 1.5% vs short TMDX 1.5% to capture relative value (GMED EPS +3.9% vs TMDX already priced for aggressive revenue growth); close or rebalance within 3–6 months around hospital capex announcements.
• Reduce broad-capex MedTech ETF exposure (e.g., IHI) by 5–10% and reallocate into software/recurring-revenue healthcare names or HIMS-like hybrids within 30 days if US CPI prints continue to ease and Fed rate cut expectations firm for H1 2026.
• Set conditional buys: add 1–2% to TMDX only on a pullback ≥15% OR if third-party fleet utilization >60% reported within 6 months; monitor Medicare reimbursement proposals and hospital procurement budgets as primary triggers.